房颤合并癌症患者使用NOAC与华法林的临床结局:全国队列研究
本研究基于台湾全民健康保险数据库,纳入2012年6月至2017年12月房颤合并癌症患者6274例使用NOAC和1681例使用华法林,采用倾向评分稳定加权平衡协变量。结果显示,与华法林相比,NOAC与较低的主要不良心血管事件、主要不良肢体事件、静脉血栓和主要出血风险相关;在75岁以下患者中NOAC与较低的主要不良心血管事件和静脉血栓风险相关,但在75岁及以上患者中未观察到该关联。
要点
- 房颤合并癌症患者中,NOAC较华法林降低主要不良心血管事件、肢体事件、静脉血栓和主要出血风险。
- NOAC的获益在卒中史、不同癌症类型及局部/区域/转移阶段患者中一致。
- 75岁以下患者NOAC与较低的主要不良心血管事件和静脉血栓风险相关,75岁及以上未观察到。
核心结论
- 对于多数房颤合并癌症患者,应考虑使用NOAC而非华法林进行血栓预防。
研究设计与样本
- 台湾全民健康保险研究数据库的全国性回顾性队列研究,纳入2012年6月1日至2017年12月31日房颤合并癌症患者,NOAC组6274例,华法林组1681例,采用倾向评分稳定加权平衡协变量。
主要发现
- NOAC组中阿哌沙班1031例、达比加群1758例、艾多沙班411例、利伐沙班3074例。
- 倾向评分稳定加权后,NOAC与华法林相比,主要不良心血管事件风险比为0.63(95%CI 0.50–0.80;P=0.0001)。
- NOAC与华法林相比,主要不良肢体事件风险比为0.41(95%CI 0.24–0.70;P=0.0010)。
- NOAC与华法林相比,静脉血栓风险比为0.37(95%CI 0.23–0.61;P<0.0001)。
- NOAC与华法林相比,主要出血风险比为0.73(95%CI 0.56–0.94;P=0.0171)。
关键数值与推荐
- 在卒中史患者、不同癌症类型及局部、区域或转移阶段癌症患者中,NOAC与华法林的结局关联一致(交互作用P>0.05)。
- 与华法林相比,NOAC在75岁以下患者中与较低的主要不良心血管事件和静脉血栓风险相关,但在75岁及以上患者中未观察到该关联(交互作用P<0.05)。
临床怎么用
- 房颤合并癌症患者可优先考虑NOAC而非华法林进行抗凝,但75岁及以上患者需个体化评估。
局限性
- 本研究为回顾性队列研究,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Data on clinical outcomes for nonvitamin K antagonist oral anticoagulant (NOACs) and warfarin in patients with atrial fibrillation and cancer are limited, and patients with active cancer were excluded from randomized trials. We investigated the effectiveness and safety for NOACs versus warfarin among patients with atrial fibrillation with cancer. METHODS: In this nationwide retrospective cohort study from Taiwan National Health Insurance Research Database, we identified a total of 6274 and 1681 consecutive patients with atrial fibrillation with cancer taking NOACs and warfarin from June 1, 2012, to December 31, 2017, respectively. Propensity score stabilized weighting was used to balance covariates across study groups. RESULTS: There were 1031, 1758, 411, and 3074 patients treated with apixaban, dabigatran, edoxaban, and rivaroxaban, respectively. After propensity score stabilized weighting, NOAC was associated with a lower risk of major adverse cardiovascular events (hazard ratio, 0.63 [95% CI, 0.50–0.80]; P=0.0001), major adverse limb events (hazard ratio, 0.41 [95% CI, 0.24–0.70]; P=0.0010), venous thrombosis (hazard ratio, 0.37 [95% CI, 0.23–0.61]; P<0.0001), and major bleeding (hazard ratio, 0.73 [95% CI, 0.56–0.94]; P=0.0171) compared with warfarin. The outcomes were consistent with either direct thrombin inhibitor (dabigatran) or factor Xa inhibitor (apixaban, edoxaban, and rivaroxaban) use, among patients with stroke history, and among patients with different type of cancer and local, regional, or metastatic stage of cancer (P interaction >0.05). When compared with warfarin, NOAC was associated with lower risk of major adverse cardiovascular event, and venous thrombosis in patients aged <75 but not in those aged ≥75 years (P interaction <0.05). CONCLUSIONS: Thromboprophylaxis with NOACs rather than warfarin should be considered for the majority of the atrial fibrillation population with cancer.
引用
- Chan YH, Chao TF, Lee HF, et al. Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study. Stroke. 2021. PMID: 34233467. doi:10.1161/STROKEAHA.120.033470
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。